Want to see SLS full AI Analyst Report?
SLS Stock Chart & Stats
$11.32
-$1.02(-8.27%)
At close: 4:00 PM EDT
$11.32
-$1.02(-8.27%)
Day’s Range― - ―
52-Week Range$1.39 - $15.88
Previous CloseN/A
Volume6.73M
Average Volume (3M)9.61M
Market Cap
$2.65B
Enterprise Value$2.65K
Total Cash (Recent Filing)$138.44M
Total Debt (Recent Filing)$737.00K
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Nov 18, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding201,945,710
10 Day Avg. Volume6,840,242
30 Day Avg. Volume9,611,115
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)5.80
Price to Sales (P/S)0.00
P/FCF Ratio-14.48
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$27.50Price Target Upside142.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$36.13M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces solvency and interest-burden risk, giving SELLAS greater flexibility to fund clinical development. The repaired equity base also provides a stronger financial platform than the negative-equity position reported in 2023.
Improved LiquidityThe larger cash balance and additional warrant proceeds extend funding capacity for operations and clinical programs. This can reduce near-term financing pressure, although the capital was obtained through additional equity issuance.
Partnered GPS Commercialization PotentialAn exclusive regional partner provides external development and commercialization resources for GPS while preserving potential milestone economics. If the program advances, this structure could create non-dilutive value beyond SELLAS’s internal funding capacity.
Bears Say
No Current Commercial RevenueSELLAS lacks recurring commercial revenue and remains dependent on clinical development success to establish operating scale. Persistent losses indicate that the business model has not yet demonstrated sustainable earnings or a self-funding revenue base.
Persistent Cash Burn And Dilution RiskNegative cash generation means SELLAS must continue relying on external capital to fund operations. Equity-linked financing can extend the runway, but recurring issuance transfers value from existing holders and leaves funding risk tied to market access.
Adverse Arbitration OutcomeThe binding ruling removes a potential near-term contractual recovery and imposes an additional cash cost. It also leaves the Greater China GPS relationship dependent on the existing license terms rather than a more favorable resolution for SELLAS.
SELLAS Life Sciences Group News
SLS FAQ
What was Sellas Life Sciences Group’s price range in the past 12 months?
Sellas Life Sciences Group lowest stock price was $1.39 and its highest was $15.88 in the past 12 months.
What is Sellas Life Sciences Group’s market cap?
Sellas Life Sciences Group’s market cap is $2.65B.
When is Sellas Life Sciences Group’s upcoming earnings report date?
Sellas Life Sciences Group’s upcoming earnings report date is Nov 18, 2026 which is in 90 days.
How were Sellas Life Sciences Group’s earnings last quarter?
Sellas Life Sciences Group released its earnings results on Aug 11, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.045 by -$0.005.
Is Sellas Life Sciences Group overvalued?
According to Wall Street analysts Sellas Life Sciences Group’s price is currently Undervalued.
Does Sellas Life Sciences Group pay dividends?
Sellas Life Sciences Group does not currently pay dividends.
What is Sellas Life Sciences Group’s EPS estimate?
Sellas Life Sciences Group’s EPS estimate is -0.05.
How many shares outstanding does Sellas Life Sciences Group have?
Sellas Life Sciences Group has 201,945,710 shares outstanding.
What happened to Sellas Life Sciences Group’s price movement after its last earnings report?
Sellas Life Sciences Group reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.045. Following the earnings report the stock price went up 6.516%.
Which hedge fund is a major shareholder of Sellas Life Sciences Group?
Currently, no hedge funds are holding shares in SLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SELLAS Life Sciences Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.50 (142.93% Upside)
$27.50 (142.93% Upside)
Blogger Sentiment
Bullish
SLS Sentiment 93%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 88.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
518.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
350.03%
Trailing 12-Months
Company Description
Sellas Life Sciences Group
SELLAS Life Sciences Group, Inc. (SLS) is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies. The company’s pipeline is centered on peptide-based immunotherapies and related oncology programs, with its lead clinical candidate being galinpepimut-S (GPS), an investigational WT1-targeting cancer immunotherapy evaluated across multiple cancer indications, and an additional program commonly referred to as nelipepimut-S (NPS).
SLS Stock 12 Month Forecast
Average Price Target
$27.50
▲(142.93% Upside)
Technical Analysis
Xencor
―
Iovance Biotherapeutics
―
Arvinas Holding Company
―
Oric Pharmaceuticals
―
Nanobiotix
―
Ownership Overview
1.66% Insiders
6.11% Mutual Funds
7.06% Other Institutional Investors
70.65% Public Companies and
Individual Investors